

- AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from *Taxus brevifolia*. *J. Am. Chem. Soc.* 1971;93:2325-7.
9. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. *Nature* 1979;277:665-7.
10. Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. *J. Clin. Oncol.* 1999;17:93-100.
11. Geyer CE Jr, Green SJ, Moynour CM, O'Sullivan J, Goodwin DK, Canfield VA, et al. Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study. *Breast Cancer Res. Treat.* 1998;51:169-181.
12. Davidson NM, Paclitaxel. *Lancet* 1995;345:1448.
13. Gelmon K. The taxoids: paclitaxel and docetaxel. *Lancet* 1994;344:1267-72.
14. Hortobagyi GN, Holmes FA, Optimal dosing of paclitaxel and doxorubicin in metastatic breast cancer. *Semin. Oncol.* 1997;24:S4-7.
15. Chen CM, Chang HT, Mok KT, Liu CI, Tsai CC, Jou NW, et al. Analysis of prognostic factors in Chinese women with breast cancer in southern Taiwan. *Chin. Med. J.* 1999;62:717-23.
16. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. *J. Clin. Oncol.* 1999;17:485-93.
17. Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. *J. Clin. Oncol.* 1999;17:3082-90.
18. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, et al. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. *Ann. Oncol.* 1999;10:403-11.
19. Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. *J. Clin. Oncol.* 1999;17:3403-11.
20. Romero AL, Langhi M, Perez J, Romero AJ, Machiavelli M, Lacava J, et al. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. *J. Clin. Oncol.* 1999;17:74-81.
21. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. *J. Natl. Cancer Inst.* 1991;83:1797-805.
22. Costanzo FD, Sdrobolini A, Manzione L, Bilancia D, Acito L, Gasperoni S, et al. Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. *Breast Cancer Res. Treat.* 1999;54:165-71.
23. Apfel SC. Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors. *Cancer Invest.* 2000;18:564-73.
24. Mayerhofer K, Bodner-Adler B, Bodner K, Leodolter S, Kainz C. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity. *Anticancer Res.* 2000;20:4047-50.